Precirix
Precirix, of Brussels, develops radiopharmaceuticals built on small single-domain antibody fragments that carry a radioactive isotope to HER2-positive cancers. Its lead, CAM-H2, is in a phase 1/2 trial in HER2-positive breast, gastric and gastro-oesophageal cancer, including patients with brain metastases, with an imaging dose given first to confirm HER2 in the lesions.
Overview
Precirix is a clinical-stage Brussels biotechnology company developing precision radiopharmaceuticals in oncology based on single-domain antibody (sdAb) targeting. Its lead candidate CAM-H2 is a HER2-directed radiopharmaceutical in a phase 1/2 trial, initially in Canada, evaluating safety, tolerability and efficacy in HER2-positive metastatic breast, gastric and gastro-oesophageal cancer, including patients with brain metastases. Patients first receive an imaging dose to confirm HER2 expression in lesions before therapeutic dosing. In June 2023 Precirix announced production of a first clinical trial batch of CAM-H2 at Evergreen Theragnostics in New Jersey to support expansion of the trial to the United States.
Notes
top- Financing (a EUR 80 million Series B reported by Fierce Biotech, whose page returned HTTP 403) is omitted as unsourced. Current operating status is uncertain given the offline website.
Similar pages
not linked directly; found by shared links- TechnologyHER2 PET
Shares HER2-positive breast cancer, HER2.
- BottleneckWrong doses
Shares HER2-positive breast cancer, Radioligand therapy (beta emitters).
- PersonJason S. Lewis
Shares HER2, Radioligand therapy (beta emitters).
- IndicationOsteosarcoma
Shares HER2, Radioligand therapy (beta emitters).